Axsome Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Axsome Therapeutics generated cash of -$145,080,000, which is less than the previous year. Cash used in financing activities reached the amount of $331,013,000 last year. Net change in cash is therefore $185,351,000.
Cash Flow
| 2014 | -4.59M | 0 | 5.12M |
|---|---|---|---|
| 2015 | -7.43M | -20.19K | 52.87M |
| 2016 | -21.28M | -104.56K | 9.96M |
| 2017 | -26.47M | -9.89K | 23.88M |
| 2018 | -30.05M | -32.69K | 10.03M |
| 2019 | -46.37M | -16.12K | 252.38M |
| 2020 | -78.45M | -45.89K | 42.41M |
| 2021 | -108.22M | -307.54K | 11.12M |
| 2022 | -116.51M | -53.70M | 284.58M |
| 2023 | -145.08M | -582K | 331.01M |
AXSM Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 200.84M | 86.47M | 183.87M | 219.96M | 13.96M | 34.02M | 36.61M | 48.03M | 2.61M | 2.08M |
Operating activities | ||||||||||
Net income | -239.23M | -187.13M | -130.40M | -102.90M | -68.34M | -30.96M | -28.94M | -27.20M | -10.55M | -6.00M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 6.83M | 5.56M | 1.15M | 77.71K | 37.33K | 48.93K | 42.55K | 20.48K | 3.54K | 0 |
Stock-based compensation expense | 62.62M | 37.72M | 20.80M | 14.75M | 6.11M | 0 | 2.07M | 2.03M | 803.27K | 376.80K |
| Deferred income tax benefit | 62.62M | 37.72M | 20.80M | 14.75M | 6.11M | 0 | 2.07M | 2.03M | 803.27K | 376.80K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -57.12M | -37.69M | 5.53K | 177.5K | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | -8.15M | -5.27M | -5.53K | -177.5K | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 2.07M | 25.45M | -354.69K | 2.56M | 7.25M | 251.78K | -645.71K | 2.18M | 1.13M | 598.83K |
Cash generated by operating activities | -145.08M | -116.51M | -108.22M | -78.45M | -46.37M | -30.05M | -26.47M | -21.28M | -7.43M | -4.59M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -582K | -702.10K | -307.54K | -45.89K | -16.12K | -32.69K | -9.89K | -104.56K | -20.19K | 0 |
Acquisitions Net | 0 | -53M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -582K | -53.70M | -307.54K | -45.89K | -16.12K | -32.69K | -9.89K | -104.56K | -20.19K | 0 |
Financing activities | ||||||||||
Common Stock Issued | 258.75M | 243.76M | 7.21M | 14.12M | 238.23M | 12.88M | 23.67M | 0 | 45.54M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | -175.71K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 85M | 45M | 0 | -21.66M | 12.76M | -3.33M | -277.77K | 0 | 7.34M | -21K |
Cash used in financing activities | 331.01M | 284.58M | 11.12M | 42.41M | 252.38M | 10.03M | 23.88M | 9.96M | 52.87M | 5.12M |
Net Change In Cash | 185.35M | 114.36M | -97.40M | -36.08M | 205.99M | -20.05M | -2.59M | -11.41M | 45.41M | 529.97K |
Cash at end of period | 386.19M | 200.84M | 86.47M | 183.87M | 219.96M | 13.96M | 34.02M | 36.61M | 48.03M | 2.61M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |